HER2 is overexpressed in the tumors of 15‐20% of breast cancer patients, and trastuzumab, a monoclonal antibody targeting HER2, plays a role in the treatment of both early and advanced breast cancer.253. The gene discussed is ERBB2; the disease is breast carcinoma.